Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance, challenges remain in reaching targeted brain regions, improving predictive modelling, ensuring efficacy and penetrance, and developing safer, targeted delivery approaches.

Join 100+ industry experts spanning neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, delivery specialists, and more at the 7th CNS Drug Delivery Summit to collaborate, network, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain.

Gain actionable insights from case studies, presentations, and deep-dive discussions on CNS drug delivery strategies covering systemic and local delivery, blood-brain barrier targeting, RMT modulation, and emerging modalities from Biogen, Sanofi, Merck, UCB, Eli Lilly, Alnylam, Voyager, and more, to advance brain access and accelerate CNS therapy development.

View the event here.